How many Deferred Share Units does Manuel Hidalgo Medina hold after the latest BMY transaction?

After the reported transaction, Manuel Hidalgo Medina beneficially owns 22,763.938 Deferred Share Units. This figure includes the new 3,996.367-unit grant plus prior deferred compensation and dividends reinvested under Bristol Myers Squibb’s 1987 Deferred Compensation Plan for Non-Employee Directors.

At what price were Manuel Hidalgo Medina’s new Deferred Share Units recorded for BMY?

The 3,996.367 Deferred Share Units were recorded at a reference price of $55.05 per unit. This price is used for reporting purposes on the derivative security and reflects the value assigned to the Deferred Share Units linked to Bristol Myers Squibb common stock.

When will Manuel Hidalgo Medina’s BMY Deferred Share Units convert into common stock?

Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when he ceases to be a director or on a future date he previously specified, according to the plan’s terms.

What plan governs Manuel Hidalgo Medina’s Deferred Share Units at Bristol Myers Squibb (BMY)?

The Deferred Share Units are tied to the 1987 Deferred Compensation Plan for Non-Employee Directors. His reported holdings include deferred compensation amounts and dividends that have been automatically reinvested under this Bristol Myers Squibb director compensation program.

Is Manuel Hidalgo Medina’s ownership of BMY Deferred Share Units direct or indirect?

The filing classifies Manuel Hidalgo Medina’s 22,763.938 Deferred Share Units as directly owned. No indirect ownership entities, such as trusts or partnerships, are indicated in the ownership line or footnotes for this particular transaction.

Bristol Myers director granted 3,996 deferred units

Bristol Myers Squibb director Manuel Hidalgo Medina reported an award of 3,996.367 Deferred Share Units on common stock, effective February 1, 2026, at a reference price of $55.05 per unit.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bristol Myers Squibb director Manuel Hidalgo Medina reported an award of 3,996.367 Deferred Share Units on common stock, effective February 1, 2026, at a reference price of $55.05 per unit. Following this grant, he holds 22,763.938 Deferred Share Units in total, all reported as directly owned.

Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. According to the disclosure, these units become settleable when he ceases to be a director or on a future date he previously specified. The total also reflects deferred compensation and dividends that have been reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Insider Trade Summary

Grant/Award: 3,996.367 shares

Grant/Award 1 txn

Insider Hidalgo Medina Manuel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	3,996.367	$55.05	$220K

Holdings After Transaction: Deferred Share Units — 22,763.938 contracts (Direct)

Footnotes (2)

F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bristol Myers Squibb (BMY) disclose about Manuel Hidalgo Medina in this Form 4?

Bristol Myers Squibb reported that director Manuel Hidalgo Medina received 3,996.367 Deferred Share Units on February 1, 2026. These units are tied to the company’s common stock and increase his total Deferred Share Units to 22,763.938, all held in direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/03/2026 - 04:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hidalgo Medina Manuel

(Last)

(First)

(Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON

08543

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Share Units	⁽¹⁾	02/01/2026		A		3,996.367		⁽¹⁾	⁽¹⁾	Common Stock, $0.10 par value	3,996.367	$55.05	22,763.938⁽²⁾	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Manuel Hidalgo Medina	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.